eTS 1198Alternative Names: eTS-1198
Latest Information Update: 03 Oct 2015
At a glance
- Originator e-Therapeutics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 19 Jan 2007 Phase-II clinical trials in Meticillin-resistant Staphylococcus aureus infections in United Kingdom (unspecified route)